TCIM
GNMX

TIAA CREF Investment Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

TIAA CREF Investment Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-97,719
Closed -$182K – 3214
2017
Q1 		$182K Buy
97,719
+13,966
+17% +$63.2K ﹤0.01% 3006
2016
Q4 		$434K Buy
83,753
+2,727
+3% +$14.3K ﹤0.01% 2892
2016
Q3 		$451 Hold
81,026
– – ﹤0.01% 2887
2016
Q2 		$450K Buy
81,026
+19,246
+31% +$101K ﹤0.01% 2905
2016
Q1 		$272K Sell
61,780
-21,568
-26% -$88.8K ﹤0.01% 2931
2015
Q4 		$502K Buy
83,348
+30,700
+58% +$208K ﹤0.01% 2892
2015
Q3 		$412K Hold
52,648
– – ﹤0.01% 2944
2015
Q2 		$323K Buy
+52,648
New +$408K ﹤0.01% 3057

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

TIAA CREF Investment Management's GNMX Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 97,719 shares — an estimated $182K sold.

TIAA CREF Investment Management first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $502K in Q4 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 97,719 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $182K.
  • TIAA CREF Investment Management first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
  • TIAA CREF Investment Management's Aevi Genomic Medicine Inc position peaked at $502K in Q4 2015.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.